{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:49:00Z","timestamp":1793504940566,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2024GXNSFBA010100"],"award-info":[{"award-number":["2024GXNSFBA010100"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2024GXNSFAA010190"],"award-info":[{"award-number":["2024GXNSFAA010190"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2024GXNSFFA010015"],"award-info":[{"award-number":["2024GXNSFFA010015"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460715"],"award-info":[{"award-number":["82460715"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bioorg.2025.108393","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T07:44:49Z","timestamp":1742543089000},"page":"108393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A novel MMP-9 inhibitor exhibits selective inhibition in non-small-cell lung cancer harboring EGFR T790M mutation by blocking EGFR\/STAT3 signaling pathway"],"prefix":"10.1016","volume":"159","author":[{"given":"Liangping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2023","key":"10.1016\/j.bioorg.2025.108393_bb0005","first-page":"17","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.108393_bb0010","doi-asserted-by":"crossref","unstructured":"F. Bray, J. Ferlay, I. Soerjomataram, et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 68 (2018) 394\u2013424.","DOI":"10.3322\/caac.21492"},{"key":"10.1016\/j.bioorg.2025.108393_bb0015","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108393_bb0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","article-title":"Worldwide frequency of commonly detected EGFR mutations","volume":"142","author":"Graham","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.bioorg.2025.108393_bb0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108393_bb0030","first-page":"853","article-title":"Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR, future","volume":"8","author":"Lim","year":"2016","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108393_bb0035","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0040","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial","volume":"20","author":"Herbst","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0045","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000490949","article-title":"Clinical impact of post-progression survival on overall survival in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line EGFR tyrosine kinase inhibitors","volume":"63","author":"Imai","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.bioorg.2025.108393_bb0050","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"36","author":"Mok","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0060","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.bioorg.2025.108393_bb0070","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108393_bb0075","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108393_bb0080","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/0008-5472.CAN-09-3106","article-title":"Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation","volume":"70","author":"Sos","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108393_bb0085","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1535-7163.MCT-11-0750","article-title":"The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor","volume":"11","author":"Kim","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108393_bb0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108393_bb0095","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.3390\/ijms23136936","article-title":"Acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer: how do we overcome it?","volume":"23","author":"Bertoli","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108393_bb0100","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108393_bb0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","article-title":"Aurora kinase a drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer","volume":"25","author":"Shah","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108393_bb0110","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.108393_bb0115","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1111\/bph.14793","article-title":"Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutations","volume":"176","author":"Yang","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0120","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108393_bb0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108393_bb0130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108393_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-016-0290-1","article-title":"EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0140","doi-asserted-by":"crossref","first-page":"11815","DOI":"10.1038\/ncomms11815","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108393_bb0145","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.lungcan.2017.04.004","article-title":"Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC","volume":"108","author":"Knebel","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2025.108393_bb0150","doi-asserted-by":"crossref","first-page":"18609","DOI":"10.18632\/oncotarget.14506","article-title":"Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: a case report","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108393_bb0155","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","article-title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC","volume":"3","author":"Walter","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108393_bb0160","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.3390\/cancers14071847","article-title":"MMP9: a tough target for targeted therapy for cancer","volume":"14","author":"Augoff","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.108393_bb0165","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/LBR.0000000000000094","article-title":"Matrix metalloproteinase-9 expression in lung cancer patients and its relation to serum mmp-9 activity, pathologic type, and prognosis","volume":"21","author":"El-Badrawy","year":"2014","journal-title":"J. Bronchology Interv. Pulmonol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0170","doi-asserted-by":"crossref","first-page":"1195426","DOI":"10.3389\/fonc.2023.1195426","article-title":"The multifaceted roles of matrix metalloproteinases in lung cancer","volume":"13","author":"Wei","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11010-018-3417-6","article-title":"Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cells","volume":"452","author":"Majumder","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2025.108393_bb0180","doi-asserted-by":"crossref","first-page":"68270","DOI":"10.18632\/oncotarget.19295","article-title":"Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL\/2 murine lung cancer","volume":"8","author":"Du","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108393_bb0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2018.02.032","article-title":"CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib","volume":"422","author":"Gou","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108393_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044798","article-title":"Apoptosis induced by knockdown of uPAR and MMP-9 is mediated by inactivation of EGFR\/STAT3 signaling in medulloblastoma","volume":"7","author":"Kotipatruni","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2025.108393_bb0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s10020-018-0035-4","article-title":"The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer","volume":"24","author":"Mandel","year":"2018","journal-title":"Mol. Med."},{"key":"10.1016\/j.bioorg.2025.108393_bb0200","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/glia.20851","article-title":"MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK\/ERK pathway","volume":"57","author":"Chattopadhyay","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.bioorg.2025.108393_bb0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jcp.25426","article-title":"Ginkgolic acid inhibits invasion and migration and TGF-\u03b2-induced EMT of lung cancer cells through PI3K\/Akt\/mTOR inactivation","volume":"232","author":"Baek","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0210","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.2147\/OTT.S134813","article-title":"Role of matrix metalloproteinase-9 in transforming growth factor-\u03b21-induced epithelial-mesenchymal transition in esophageal squamous cell carcinoma","volume":"10","author":"Bai","year":"2017","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.bioorg.2025.108393_bb0215","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12957-020-01958-w","article-title":"Role of MMP-9 in epithelial-mesenchymal transition of thyroid cancer","volume":"18","author":"Li","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.bioorg.2025.108393_bb0220","doi-asserted-by":"crossref","first-page":"14824","DOI":"10.1074\/jbc.M113.451336","article-title":"Transforming growth factor-\u03b21 (TGF-\u03b21)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts","volume":"288","author":"Midgley","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108393_bb0225","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.lfs.2018.07.035","article-title":"Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt\/NF-\u03baB signaling","volume":"208","author":"Rasheduzzaman","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2025.108393_bb0230","doi-asserted-by":"crossref","unstructured":"Y.P. Kwan, M.H.Y Teo, J.C.W Lim, et al., LRG1 promotes metastatic dissemination of melanoma through regulating EGFR\/STAT3 signalling, Cancers 13 (2021) 3279.","DOI":"10.3390\/cancers13133279"},{"key":"10.1016\/j.bioorg.2025.108393_bb0235","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/1078-0432.CCR-12-0792","article-title":"Targeting stat3 abrogates EGFR inhibitor resistance in cancer","volume":"18","author":"Sen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108393_bb0240","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1039\/D4MD00384E","article-title":"Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024)","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108393_bb0245","doi-asserted-by":"crossref","unstructured":"T.C. Appleby, A.E Greenstein, M. Hung, et al., Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9, J. Biol. Chem. 292(2017) 6810\u20136820.","DOI":"10.1074\/jbc.M116.760579"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825002731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825002731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:24:11Z","timestamp":1762223051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825002731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":49,"alternative-id":["S0045206825002731"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108393","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel MMP-9 inhibitor exhibits selective inhibition in non-small-cell lung cancer harboring EGFR T790M mutation by blocking EGFR\/STAT3 signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108393"}}